Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 2010

View Archived Issues

Cornerstone completes private equity financing for CPI-613

ResearchPoint and Azaya enroll first patient in phase I ATI-1123 study

Biomarkers for pancreatic cancer identified via proximity ligation assay

Neuroprotection seen with MGF-24 may be beneficial in Parkinson's disease

Studies with tropisetron indicate that 5-HT3R is an antiobesity target

European Commission approves Roche's Herceptin for HER2-positive stomach cancer

Ark enrolls first patient in phase I/IIa trial of EG-011 in refractory angina

Palatin Technologies claims MCR ligands for the treatment of sexual dysfunction

Merck & Co. discloses NS5B inhibitors for HCV infection

National Health Research Institutes describes coumarins for cancer therapy

University of Toledo reports M1 agonists for the treatment of mental disorders

GlaxoSmithKline identifies novel PI3K inhibitors for asthma therapy

New highly sensitive assay links troponin T concentrations to CAD

Sodium phenylbutyrate reduces macrophage ER stress and lipotoxicity in atherosclerosis

Pharmasset initiates phase IIa PSI-7977 trial in HCV

Aegera initiates phase II AEG-35156 study for hepatocellular carcinoma

FDA approves Bayer's phase I study with personalized vaccine from tobacco plants

NCI initiates study for ImmuneRegen's vaccine adjuvant candidate

FDA extends PDUFA action date for Sepracor's NDA for Stedesa

MedCI enters alliance with Genta to secure licensing partners for tesetaxel

Repros receives guidance from FDA on Androxal in secondary hypogonadism

Cytokinetics reports data from phase I multiple dose CK-2017357 trial

Tripep presents update for ChronVac-C-study

ALS Therapy Development Institute and Oxford BioMedica extend collaboration

Warner Chilcott received complete response letter for low dose oral contraceptive

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...